Shares in Altimmune Inc. and Angion Biomedica Corp. were sharply down after the companies announced trial disappointments from a nasal COVID-19 vaccine and two investigational therapies. Altimmune was worst hit, with shares (NASDAQ:ALT) dropping 38% to $9.80 June 30 after announcing its nasal COVID-19 vaccine did not produce enough immune response and axing an immunotherapy trial after encountering problems finding enough subjects.
LONDON – Moves to expand the legal remit of the European Medicines Agency (EMA) and give it more powers to deal with the COVID-19 pandemic and future health emergencies are moving to fruition, after the European Parliament and national health ministers in the European Council separately voted through the proposal.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Advanced Accelerator Applications, Avacta, Avicenna.AI, B. Braun, Bioivt, Cancer Targeted Technology, Cognetivity Neurosciences, Ethicon, Medline Industries, Merck, Neuroloop, Novacyt, Nuance, Orthofix Medical, Qiagen, Teleflex, Valley Biomedical Products & Services, Verogen.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abiomed, Attana, Front Line Medical, Galderma, Neuros Medical.
As a first step in developing a portfolio of COVID-19 therapies, the European Commission identified five promising candidates June 29, including four monoclonal antibodies under rolling review at the EMA and an immunosuppressant that could have its marketing authorization extended to include the treatment of COVID-19 infections.
RSS
